Department of Neurology, Show Chwan Memorial Hospital, Chunghwa, 500, Taiwan.
MR-Guided Focus Ultrasound Center, Chang Bin Shaw Chwan Memorial Hospital, Changhwa, 505, Taiwan.
Sci Rep. 2022 Oct 26;12(1):17919. doi: 10.1038/s41598-022-22647-6.
Amyloid plaques and tau tangles are pathological hallmarks of Alzheimer's disease (AD). Parkinson's disease (PD) results from the accumulation of α-synuclein. TAR DNA-binding protein (TDP-43) and total tau protein (T-Tau) play roles in FTD pathology. All of the pathological evidence was found in the biopsy. However, it is impossible to perform stein examinations in clinical practice. Assays of biomarkers in plasma would be convenient. It would be better to investigate the combinations of various biomarkers in AD, PD and FTD. Ninety-one subjects without neurodegenerative diseases, 76 patients with amnesic mild cognitive impairment (aMCI) or AD dementia, combined as AD family, were enrolled. One hundred and nine PD patients with normal cognition (PD-NC) or dementia (PDD), combined as PD family, were enrolled. Twenty-five FTD patients were enrolled for assays of plasma amyloid β 1-40 (Aβ), Aβ, T-Tau, α-synuclein and TDP-43 using immunomagnetic reduction (IMR). The results show that Aβs and T-Tau are major domains in AD family. α-synuclein is highly dominant in PD family. FTD is closely associated with TDP-43 and T-Tau. The dominant plasma biomarkers in AD family, PD family and FTD are consistent with pathology. This implies that plasma biomarkers are promising for precise and differential assessments of AD, PD and FTD in clinical practice.
淀粉样斑块和tau 缠结是阿尔茨海默病 (AD) 的病理学标志。帕金森病 (PD) 是由α-突触核蛋白积累引起的。TAR DNA 结合蛋白 (TDP-43) 和总 tau 蛋白 (T-Tau) 在 FTD 病理学中发挥作用。所有的病理学证据都在活检中发现。然而，在临床实践中不可能进行stein 检查。血浆生物标志物的检测将更为方便。最好对 AD、PD 和 FTD 中的各种生物标志物的组合进行研究。本研究纳入了 91 名无神经退行性疾病的受试者、76 名有遗忘型轻度认知障碍 (aMCI) 或 AD 痴呆的患者（合并为 AD 组）、109 名认知正常 (PD-NC) 或痴呆 (PDD) 的 PD 患者（合并为 PD 组）和 25 名 FTD 患者，用于检测血浆淀粉样β 1-40 (Aβ)、Aβ、T-Tau、α-突触核蛋白和 TDP-43 的免疫磁还原 (IMR)。结果表明，Aβs 和 T-Tau 是 AD 组的主要领域。α-突触核蛋白在 PD 组中高度占优势。FTD 与 TDP-43 和 T-Tau 密切相关。AD 组、PD 组和 FTD 的主要血浆生物标志物与病理学一致。这意味着血浆生物标志物有望在临床实践中对 AD、PD 和 FTD 进行精确和差异化评估。
